Online inquiry

IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8897MR)

This product GTTS-WQ8897MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Chronic idiopathic urticaria research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8897MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4712MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ687MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ15396MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ12062MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ13586MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ8295MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ4137MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ918MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW